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Chronic kidney disease (CKD) is a public health problem and a recognized risk factor
for cardiovascular diseases (CVD). CKD could amplify the progression of chronic heart
failure leading to the development of type 4 cardio-renal syndrome (T4CRS). The
severity and persistence of heart failure are strongly associated with mortality risk in
T4CRS. CKD is also a catabolic state leading to renal sarcopenia which is characterized
by the loss of skeletal muscle strength and physical function. Renal sarcopenia also
promotes the development of CVD and increases the mortality in CKD patients. In
turn, heart failure developed in T4CRS could result in chronic muscle hypoperfusion
and metabolic disturbances leading to or aggravating the renal sarcopenia. The
interplay of multiple factors (e.g., comorbidities, over-activated renin-angiotensin-
aldosterone system [RAAS], sympathetic nervous system [SNS], oxidative/nitrative
stress, inflammation, etc.) may result in the progression of T4CRS and renal sarcopenia.
Among these factors, oxidative/nitrative stress plays a crucial role in the complex
pathomechanism and interrelationship between T4CRS and renal sarcopenia. In the
heart and skeletal muscle, mitochondria, nicotinamide adenine dinucleotide phosphate
(NADPH) oxidases, uncoupled nitric oxide synthase (NOS) and xanthine oxidase are
major ROS sources producing superoxide anion (O2·−) and/or hydrogen peroxide
(H2O2). O2
·− reacts with nitric oxide (NO) forming peroxynitrite (ONOO−) which is a highly
reactive nitrogen species (RNS). High levels of ROS/RNS cause lipid peroxidation, DNA
damage, interacts with both DNA repair enzymes and transcription factors, leads to the
oxidation/nitration of key proteins involved in contractility, calcium handling, metabolism,
antioxidant defense mechanisms, etc. It also activates the inflammatory response, stress
signals inducing cardiac hypertrophy, fibrosis, or cell death via different mechanisms (e.g.,
apoptosis, necrosis) and dysregulates autophagy. Therefore, the thorough understanding
of the mechanisms which lead to perturbations in oxidative/nitrative metabolism and its
relationship with pro-inflammatory, hypertrophic, fibrotic, cell death and other pathways
would help to develop strategies to counteract systemic and tissue oxidative/nitrative
stress in T4CRS and renal sarcopenia. In this review, we also focus on the effects of
some well-known and novel pharmaceuticals, nutraceuticals, and physical exercise on
cardiac and skeletal muscle oxidative/nitrative stress in T4CRS and renal sarcopenia.
Keywords: end-stage renal disease, uremic cardiomyopathy, uremic myopathy, inflammation, anti-oxidants,
renin-angiotensin-aldosterone system (RAAS), exercise training, microRNA (miR)
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INTRODUCTION
Clinical Significance and Classification of
CKD
The prevalence of CKD varies between 7 and 12% in the
general population worldwide and increases with age affecting
more than 30% of people over 65 years (Walker et al., 2013;
Musso et al., 2015; Romagnani et al., 2017). CKD is defined
as the abnormal renal structure and/or dysfunction (glomerular
filtration rate [GFR] <60 mL/min/1.73 m2) present for at least 3
months (KDIGO Work Group, 2013; Pinheiro da Silva and Vaz
da Silva, 2016). It can be classified into five stages based on GFR
values. G1 stage refers to normal (GFR >90 mL/min/1.73 m2),
G2 to mildly decreased (GFR = 60–89 mL/min/1.73 m2), G3 to
moderately decreased (GFR = 30–59 mL/min/1.73 m2), G4 to
severely decreased kidney function (GFR = 15–29 mL/min/1.73
m2) and G5 to kidney failure including end-stage renal disease
(ESRD) (GFR <15 mL/min/1.73 m2) which requires kidney
replacement therapy for survival (KDIGO Work Group, 2013;
Pinheiro da Silva and Vaz da Silva, 2016). Large population
studies have demonstrated that all stages of CKD increase the risk
of premature death mainly from CVD (Go et al., 2004; Kumar
et al., 2014). CKD and ESRD patients have a 5- to 10-fold higher
risk for developing CVD compared to age-matched controls
(Duni et al., 2017). Despite the broad availability of medications
to control the underlying diseases (e.g., hypertension, diabetes
mellitus, hyperlipidemia, etc.) and renal replacement therapy,
cardiovascular morbidity and mortality remain major challenges
in the management of CKD patients.
T4CRS
Recognition that CVD is a major cause of mortality in CKD
patients, and conversely, deterioration in kidney function is
associated with a poorer prognosis in CVD patients, led to
Abbreviations: AGEs, advanced glycation end products; AT1, angiotensin II
receptor type 1; ATP, adenosine triphosphate; CAT, catalase; CKD, chronic
kidney disease; CVD, cardiovascular diseases; CoQ10, coenzyme Q10; COX,
cyclooxygenase; CRP, C-reactive protein; DNA, deoxyribonucleic acid; eGFR,
estimated glomerular filtration rate; eNOS, endothelial nitric oxide synthase; ER,
endoplasmic reticulum; ERK-1/2, extracellular signal-regulated protein kinases
1 and 2; ESRD, end stage renal disease; FGF, fibroblast growth factor; GFR,
glomerular filtration rate; GSH, glutathione; GSH-Px, glutathione peroxidase;
GST, glutathione S-transferase; H2O2, hydrogen peroxide; HDL, high density
lipoprotein; HFpEF, heart failure with preserved ejection fraction; HFrEF,
heart failure with reduced ejection fraction; ICAM, intercellular adhesion
molecule 1; IL, interleukin; iNOS, inducible nitric oxide synthase; JNK, c-
Jun N-terminal kinase; LDL, low density lipoprotein; LVH, left ventricular
hypertrophy; MAPK, mitogen-activated protein kinase; MDA, malondialdehyde;
MPO, myeloperoxidase; NADPH oxidase, nicotinamide adenine dinucleotide
phosphate oxidase; NF-κB, nuclear factor kappa-light-chain-enhancer of activated
B cells; ·NO, nitric oxide; nNOS, neuronal nitric oxide synthase; NOXs, NADPH
oxidases; Nrf2, nuclear factor erythroid 2–related factor 2; NT-pro-BNP, N-
terminal pro-brain natriuretic peptide; O·−2 , superoxide;
·OH, hydroxyl radical;
ONOO−, peroxynitrite; PARP-1, poly-ADP-ribose-polymerase 1; PCS, p-cresyl
sulfate; PDGF, platelet-derived growth factor; PON-1, paraoxonase/arylesterase
1; RAAS, renin–angiotensin–aldosterone system; RNS, reactive nitrogen species;
ROS, reactive oxygen species; SERCA2a, sarcoplasmic reticulum calcium ATPase
2a; SNS, sympathetic nervous system; SOD, superoxide dismutase; T4CRS, type
4 cardio-renal syndrome; TBARS, thiobarbituric acid reactive substances; TGF-
β, transforming growth factor-beta; TNF-α, tumor necrosis factor-alpha; VCAM,
vascular cell adhesion molecule 1; VEGF, vascular endothelial growth factor
the introduction of the term of cardio-renal syndrome defined
by Ronco et al. (2008). The bidirectional interaction of renal
and heart failure is the key concept in cardio-renal syndrome
(Ronco et al., 2008; Kumar et al., 2014) (Figure 1). Dysfunction
of each organ can induce and perpetuate injury in the other
via complex hemodynamic, neurohormonal (e.g., over-activated
SRS, RAAS, etc.), biochemical (e.g., increased oxidative/nitrative
stress, etc.), inflammatory, and immunologic pathways (Bock
and Gottlieb, 2010; Brisco and Testani, 2014) (Figure 1). The
cardio-renal syndrome has five subtypes which classification is
based on the organ affected primarily (heart, kidney or both,
e.g., in sepsis) and the time frame (acute or chronic) (see for
reviews: Ronco et al., 2008; Husain-Syed et al., 2015). T4CRS is
the subtype in which CKD is the primary disease including, e.g.,
diabetic, hypertensive, autoimmune, etc. nephropathy forms, and
induces the progression of chronic heart failure with preserved
ejection fraction (HFpEF) and later heart failure with reduced
ejection fraction (HFrEF) (Husain-Syed et al., 2015; Pinheiro da
Silva and Vaz da Silva, 2016) (Figure 1). The CKD-associated
chronic functional, structural and electrophysiological changes of
the heart are also called uremic cardiomyopathy (Husain-Syed
et al., 2015). It is characterized by left ventricular hypertrophy
(LVH) and diastolic dysfunction in the HFpEF phase and later
interstitial fibrosis, capillary rarefication, and systolic dysfunction
in the HFrEF phase (Kocsis et al., 2012; Husain-Syed et al.,
2015) (Figure 1). Epidemiological and imaging studies supposed
that the leading manifestation of uremic cardiomyopathy is LVH
(Mark et al., 2006; Siedlecki and Muslin, 2008; Alhaj et al.,
2013). The prevalence of LVH significantly increases with the
progression of CKD (31, 50, and 90% in stages G3, G4, and
G5, respectively) (Cerasola et al., 2011; Duni et al., 2017). The
severity and persistence of LVH are strongly correlated with acute
cardiovascular events (e.g., sudden cardiac death, arrhythmias,
and acute myocardial infarction) and mortality risk in T4CRS
(Zoccali et al., 2004; Husain-Syed et al., 2015; Duni et al., 2017)
(Figure 1).
Renal Sarcopenia
CKD is also a catabolic state leading to renal sarcopenia which
is characterized by the loss of skeletal muscle strength and
physical function (Stenvinkel et al., 2016; Moorthi and Avin,
2017) (Figure 2). Catabolic pathways include e.g., activation of
the ubiquitin-proteasome system, caspase-3-mediated apoptosis,
autophagy, imbalance between the anabolic insulin/IGF1 and
catabolic myostatin signaling pathways, IL-6 and TNF-α-
mediated inflammatory pathways, defective leptin signaling and
hypothalamic melanocortin systems, over-activated SNS and
RAAS, etc. (Mitch and Du, 2004; see for detailed reviews:
Mendler et al., 2007; Wang and Mitch, 2014; Yoshida
and Delafontaine, 2015; Powers et al., 2016; Kocsis et al.,
2017) (Figure 2). These pathways might activate each other
and lead to CKD-associated complications including, e.g.,
hypertension, insulin resistance, metabolic changes, chronic
inflammatory state, malnutrition etc (Mitch and Du, 2004; Wang
and Mitch, 2014; Yoshida and Delafontaine, 2015; Powers et al.,
2016) (Figure 2). Sarcopenia is common and strongly associated
with morbidity and mortality in CKD patients especially in
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FIGURE 1 | Traditional and non-traditional cardiovascular risk factors for T4CRS. AMI, acute myocardial infarction; CKD, chronic kidney disease; CVD, cardiovascular
disease; DM, diabetes mellitus; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction, LVH:
left ventricular hypertrophy; RAAS, renin–angiotensin–aldosterone system; RNS, reactive nitrogen species; ROS, reactive oxygen species; SCD, sudden cardiac
death, SNS: sympathetic nervous system; T4CRS, type 4 cardio-renal syndrome.
those with stage G3, G4, and G5 including ESRD (GFR <45
mL/min/1.73 m2) (Carrero et al., 2013; Wang and Mitch, 2014;
Obi et al., 2015). In renal sarcopenia, the loss of skeletal muscle
strength leads to easy fatigability (Sakkas et al., 2003; Kaltsatou
et al., 2015). It can be caused by the loss and/or atrophy of
the muscle fibers (Sakkas et al., 2003; Kaltsatou et al., 2015).
In ESRD patients, atrophy and loss of type IIα and IIx fibers,
decreased capillarization of fibers, the functional deterioration in
the existing muscle mass, and reduced mitochondrial respiratory
capacity have been described (Sakkas et al., 2003; Kaltsatou et al.,
2015; Roshanravan et al., 2017).
Major Factors in the
Cardio-Reno-Muscular Crosstalk in CKD
Although CKD and CVD patients share many traditional
cardiovascular risk factors including e.g., hypertension, obesity,
dyslipidemia, diabetes mellitus, age, etc. these fail to give full
explanation for the disproportionately increased cardiovascular
mortality risk of CKD patients as compared to the general
population (Baigent et al., 2000; Ronco et al., 2008; Kumar
et al., 2014; Ortiz et al., 2014) (Figure 1). Both experimental
and clinical studies proved that non-traditional cardiovascular
risk factors specific to CKD provoked the development of LVH,
independently of pressure- and volume-overload induced by the
over-activated SNS and RAAS due to renal hypoperfusion (Raev,
1994; Nielsen et al., 1998; McMahon et al., 2000; Wolf et al., 2000;
Alhaj et al., 2013) (Figure 1). These non-traditional and CKD-
specific risk factors include e.g., uremic toxins, hyperkalemia,
and hypocalcemia, metabolic acidosis, abnormal apolipoprotein
levels, enhanced coagulability, anemia, endothelial dysfunction,
increased plasma homocysteine concentration, elevated systemic
and tissue levels of inflammatory factors, protein-energy wasting,
oxidative/nitrative stress, etc. (Parfrey et al., 1995; Fort, 2005;
Schiffrin et al., 2007; Mitsnefes et al., 2018) (Figure 1). All of
these factors might adversely affect muscle mass, performance
and exercise tolerance leading to renal sarcopenia (Negrao and
Middlekauff, 2008; Bacurau et al., 2016) (Figure 2). Moreover,
renal sarcopeniamight lead to physical inactivity which promotes
the development of cardiovascular complications including
acute myocardial infarction and chronic heart failure in CKD
patients (Wilund et al., 2010; Moorthi and Avin, 2017). Heart
failure developed in T4CRS could also result in chronic muscle
hypoperfusion and/or metabolic disturbances (Negrao and
Middlekauff, 2008; Bacurau et al., 2016). Although a myriad
of factors might contribute to the crosstalk between T4CRS
and renal sarcopenia, the precise molecular mechanisms that
induce and maintain these pathological conditions are not fully
understood yet.
Accumulating evidence suggests that elevated
oxidative/nitrative stress could be a key factor in the development
of complex biochemical, structural and functional changes
associated with T4CRS and renal sarcopenia. Understanding
the complex interactions between oxidative/nitrative stress and
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FIGURE 2 | Interplay between chronic kidney disease and sarcopenia. CKD, chronic kidney disease; CV, cardiovascular; IGF1, insulin-like growth factor 1; IL-6,
interleukin-6; RAAS, renin–angiotensin–aldosterone system; RNS, reactive nitrogen species; ROS, reactive oxygen species; SNS, sympathetic nervous system;
TNF-α, tumor necrosis factor-alpha; UPS, ubiquitin-proteasome system.
other pathological pathways (e.g., inflammation, cardiomyocyte
hypertrophy, fibrosis, cell death, etc.) is essential to develop novel
targeted therapies for T4CRS and renal sarcopenia patients. In
this review, we focus on the role of cardiac and skeletal muscle
oxidative/nitrative stress in the development of T4CRS and renal
sarcopenia. We also review the effects of some clinically used and
novel pharmaceuticals, nutraceuticals, and physical exercise on
cardiac and skeletal muscle oxidative/nitrative stress in T4CRS
and renal sarcopenia.
OXIDATIVE/NITRATIVE STRESS AND
CELLULAR DAMAGE
Oxidative/nitrative stress is characterized by increased
levels of ROS and RNS including, e.g., superoxide (O2·−),
hydrogen peroxide (H2O2), hydroxyl radical (
·OH), and
peroxynitrite (ONOO−) (Sies, 1997; Sárközy et al., 2016;
Radi, 2018). The reason for the development of increased
oxidative/nitrative stress could be the excessive production
and/or the unsatisfactory removal by the antioxidant
defense mechanisms of the highly reactive ROS/RNS
molecules (Sies, 1997; Sárközy et al., 2016; Radi, 2018)
(Figure 3).
Cellular Sources of ROS/RNS
The main enzymatic sources for ROS/RNS production are
the mitochondrial respiratory chain, NADPH oxidases,
uncoupled NOS, xanthine oxidase (XO), heme oxygenase
(HO), cyclooxygenase, lipoxygenase, cytochrome P450 system,
myeloperoxidase, etc. (Di Meo et al., 2016; Radi, 2018). Under
physiological conditions, a low amount of ROS/RNS is constantly
produced by the mitochondria (Bartz et al., 2015). Mitochondrial
ROS production is mainly in the form of O2·− via a single
electron transport to molecular oxygen in the respiratory
chain at complexes I and III (Bartz et al., 2015) (Figure 3).
Mitochondrial RNS production is mainly in the form of
ONOO− when O2·− reacts with NO produced by mitochondrial
nitric oxide synthase (mtNOS) or inducible nitric oxide synthase
(iNOS) isoforms (see for detailed review: Shvedova et al., 2018)
(Figure 3). Under normal conditions, mitochondrial O2·−
is degraded spontaneously or by mitochondrial superoxide
dismutase (SOD2 isoform) to H2O2. It could either turn to
·OH and water via the Fenton reaction or move from the
mitochondrion to the cytoplasm (Bartz et al., 2015; Di Meo
et al., 2016). Here, it could be catalyzed to water and oxygen by
catalase (CAT), glutathione peroxidases (GSH-Px), glutathione
(GSH), peroxiredoxins, etc. (Bartz et al., 2015; Di Meo et al.,
2016) (Figure 3).
Evidence suggests an interplay between mitochondria and
other cellular ROS/RNS sources (Di Meo et al., 2016). Thus,
the activation of one can result in the activation of other
ROS/RNS sources (Di Meo et al., 2016). In the heart and skeletal
muscle, the transmembrane NADPH oxidases (NOXs) also play
an important role in the cytoplasmic and mitochondrial ROS
production (Rubattu et al., 2013). NADPH serves as an electron
donor to reduce oxygen and produce O2·− or H2O2 (Sirker
et al., 2011; Schramm et al., 2012; Hafstad et al., 2013) (Figure 3).
Out of the seven NADPH oxidase family members, NOX2 and
NOX4 are the main isoforms in cardiomyocytes and skeletal
muscle (Sirker et al., 2011; Schramm et al., 2012; Hafstad et al.,
2013; Ferreira and Laitano, 2016). NOX2 is present in the plasma
membrane and phagosome membranes (Altenhöfer et al., 2012).
NOX4 is localized in the plasma membrane, mitochondrial,
and endoplasmic reticulum membranes and nucleus (Altenhöfer
et al., 2012). XO is another significant cytoplasmic source of ROS
which produces O2·− by catalyzing the reaction of hypoxanthine
to xanthine and then uric acid in the last phase of purine
metabolism both in the cardiomyocytes and skeletal muscle cells
(Wilson et al., 2017). In the cytoplasm, O2·− and H2O2 could be
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FIGURE 3 | Oxidative/nitrative stress and cellular damage in the heart and skeletal muscle. AngII, angiotensin II; CAT, catalase; DNA, deoxyribonucleic acid; ETC,
electron transport chain; ET-1, endothelin-1; Fe2+/3+, iron ions; GSH, glutathione; GSH-Px, glutathione peroxidase; H2O, water; H2O2, hydrogen peroxide; HOCl,
hypochlorous acid; iNOS, inducible nitric oxide synthase; JNK, c-Jun N-terminal kinase; ly, lymphocytes; MAPK, mitogen-activated protein kinase; mo, monocytes;
MPO, myeloperoxidase; mtNOS, mitochondrial nitric oxide synthase; NADPH oxidase, nicotinamide adenine dinucleotide phosphate; NF-κB, nuclear factor
kappa-light-chain-enhancer of activated B cells; ng, neutrophil granulocytes; NO, nitric oxide; NOX4, NADPH oxidase 4; O·−2 , superoxide; OH, hydroxyl radical;
PARP-1, poly-ADP-ribose-polymerase 1; RNS, reactive nitrogen species; ROS, reactive oxygen species; TNF-α, tumor necrosis factor-alpha.
either eliminated by the above mentioned enzymatic (e.g., SOD,
CAT, etc.) and non-enzymatic (e.g., glutathione, vitamins A, C,
and E, etc.) antioxidant defense mechanisms, or react with NO
to form the highly reactive ONOO− (see for detailed review:
Pacher and Szabo, 2008) (Figure 3). NO is produced by different
isoforms of nitric oxide synthase (NOS). Both in the heart and
skeletal muscle, type I or neuronal nitric oxide synthase (nNOS)
and type III or endothelial nitric oxide synthase (eNOS) are
constitutively expressed under normal circumstances generating
low levels of NO (Modlinger et al., 2004; Carnicer et al., 2013;
Eghbalzadeh et al., 2014). Under pathophysiological conditions,
uncoupling of eNOS from its cofactor tetrahydrobiopterin (TB4)
leads to oxidative stress since uncoupled NOS produces O2·−
instead of NO and decrease the bioavailability of NO (Pacher and
Szabo, 2008). Type II or inducible nitric oxide synthase (iNOS)
is robustly up-regulated under pathophysiological circumstances
(e.g., inflammation)markedly increasing NO levels which further
reacts with O2·− producing ONOO− (Modlinger et al., 2004;
Carnicer et al., 2013; Eghbalzadeh et al., 2014) (Figure 3).
Cellular Damage Caused by ROS/RNS
Under pathophysiological conditions, high levels of ROS/RNS
cause lipid peroxidation, protein oxidation/nitration,
inactivation of enzymes, DNA damage, interacts with both
DNA repair enzymes (e.g., poly [ADP-ribose] polymerase 1
[PARP-1]) and transcription factors (e.g., NF-κB), lead to the
activation of inflammatory response (e.g., IL-1, IL-6, TNF-α,
TGF-β, etc.), stress signals (e.g., c-Jun N-terminal kinase [JNK],
p38-MAPK) or cell death via different mechanisms (e.g.,
apoptosis, necrosis, etc.), dysregulation of autophagy, etc. (see
for reviews: Graziewicz et al., 2002; Maack and Böhm, 2011;
Osterholt et al., 2013; Rubattu et al., 2013; Varga et al., 2015)
(Figure 3). In the heart and skeletal muscle, the aforementioned
mechanisms and the oxidation/nitration of proteins involved in
contractility, excitation-contraction coupling, Ca2+ handling,
metabolism, elements of the mitochondrial electron transport
chain and Krebs cycle, extracellular matrix, etc. might result in
deleterious events (Graziewicz et al., 2002; Maack and Böhm,
2011; Osterholt et al., 2013; Rubattu et al., 2013; Varga et al.,
2015) (Figure 3). Evidence suggests that chronic activation of
RAAS and SNS in heart failure also stimulates inflammation
and oxidative/nitrative stress which factors further aggravate
each other in both the heart and the kidney (Nakamura et al.,
2002; Heymes et al., 2003; Bleeke et al., 2004; Wassmann et al.,
2004). Angiotensin II has reported to activate both cardiac and
renal NADPH oxidase and subsequently the overproduction
of ROS/RNS, which in turn trigger the production of pro-
inflammatory mediators including e.g., IL-1, IL-6, TNF, TGF-β,
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etc. contributing to cardiac and renal fibrosis (Lodha et al., 2002;
Schultz et al., 2002; Ijsselmuiden et al., 2008; Zhang et al., 2012).
PATHWAYS OF SYSTEMIC
OXIDATIVE/NITRATIVE STRESS IN CKD
It is established that the interplay of multiple factors (e.g.,
impairment of renal function, comorbidities, over-activated
RAAS, elevated oxidative/nitrative stress, inflammation,
metabolic changes, etc.) could lead to the development and
progression of CKD (see for reviews: Rubattu et al., 2013; Duni
et al., 2017). These factors could activate and potentiate each
other leading to a vicious cycle. Among these factors, increased
oxidative/nitrative stress plays a key role in the complex
pathomechanism of CKD. In this section, we summarize the
major factors of CKD-induced systemic oxidative/nitrative stress
and some clinically relevant mechanisms which interact with
oxidative/nitrative stress in CKD.
Over-Production of ROS/RNS vs.
Ineffective Antioxidant Defense
Mechanisms in CKD
Elevated systemic oxidative/nitrative stress is believed to be
mainly the consequence of higher ROS/RNS production in
CKD (Bossola and Tazza, 2015; Duni et al., 2017). Reduced
clearance of pro-oxidant substances due to renal dysfunction
and impaired antioxidant defense mechanisms supposed to
play a complementary role (Duni et al., 2017). The over-
production of ROS/RNS is aggravated by patient-related (e.g.,
age, uremic toxins, chronic systemic inflammation, pro-oxidant
comorbidities including obesity, hypertension, diabetes mellitus,
etc.), and hemodialysis-related factors (e.g., membrane bio-
incompatibility, endotoxins, etc.) especially in ESRD patients
on long-term dialysis (Bossola and Tazza, 2015) (Figure 2). The
impairment of antioxidant defense mechanisms (e.g., decreased
levels of vitamin C and E, deficiency in the glutathione
scavenging system, etc.) become more pronounced only in ESRD
(Bossola and Tazza, 2015). Nuclear factor-erythroid-2-related
factor 2 (Nrf2) is a transcription factor which coordinates the
induction of several genes including antioxidant and detoxifying
enzymes and associated proteins (Kim and Vaziri, 2010; Ruiz
et al., 2013). Experimental studies have demonstrated that
CKD animals showed a significant and time-dependent decrease
in nuclear Nrf2 amount, despite the oxidative stress and
inflammation, which should have led to Nrf2 activation and
overexpression of its target genes (Kim and Vaziri, 2010; Ruiz
et al., 2013).
Increased Renal ROS/RNS Production as a
Major Cause of Systemic
Oxidative/Nitrative Stress in CKD
Systemic oxidative/nitrative stress is progressively increased
in CKD and is most prominently elevated in ESRD patients
(Dounousi et al., 2006; Small et al., 2012; Bossola and Tazza,
2015). In CKD patients, ROS levels in the blood plasma strongly
correlate with renal ROS production and NOX4 activity which is
thought to be themajor source of ROS in the kidneys (Vaziri et al.,
2007; Duni et al., 2017). NOX4 is also the predominant form of
NADPH oxidases in the mitochondrial membrane (Vaziri et al.,
2007; Duni et al., 2017). Themain pathophysiological mechanism
underlying the renal overproduction of ROS is supposed to be
the upregulation of the intrarenal RAAS (Sedeek et al., 2013;
Duni et al., 2017). It has been demonstrated that angiotensin
II-mediated activation of the AT1 receptor could increase the
renal and vascular O2·− production via NOX isoforms (Vaziri
et al., 2007; Kim et al., 2011; Duni et al., 2017). It has also been
proposed that increased oxidative/nitrative stress itself results
in accelerated progression of the kidney disease via cytotoxic
mechanisms perpetuating a vicious cycle (Dounousi et al., 2006;
Bossola and Tazza, 2015; Duni et al., 2017).
The Interplay of Increased Systemic
Oxidative/Nitrative Stress With Chronic
Inflammation in CKD
Chronic inflammation is thought to be the most common
result of the elevated oxidative/nitrative stress in CKD as a
consequence of the activation of nuclear factor-kB (NF-kB)
and other transcription factors regulating the gene expression
of pro-inflammatory cytokines and chemokines (Jin Jung
et al., 2013; Tucker et al., 2015; Wu et al., 2016; Duni
et al., 2017). Moreover, both oxidative/nitrative stress and
inflammation can amplify each other (Raizada et al., 2007; Jin
Jung et al., 2013; Tucker et al., 2015; Wu et al., 2016; Duni
et al., 2017). On the one hand, elevated oxidative/nitrative
stress stimulates recruitment and activation of leukocytes, the
formation of pro-inflammatory oxidized lipids, advanced protein
oxidation products, and advanced glycation end products (AGEs)
(Duni et al., 2017). On the other hand, activated leukocytes,
macrophages, and other cells generate ROS/RNS which further
enhances oxidative/nitrative stress (Fortuno et al., 2005; Duni
et al., 2017). Indeed, a study reported that ROS generated
by NADPH oxidase was enormously elevated in circulating
lymphocytes and monocytes even in the early stages of CKD
(Fortuno et al., 2005; Duni et al., 2017). CKD is characterized
by chronic inflammation with higher plasma concentrations of
C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis
factor a (TNF-α) and fibrinogen, and lower levels of albumin
(Kumar et al., 2014). ROS such as O2·− and H2O2 activate
NF-kB, which is inactive in the cytoplasm of normal cells,
including renal cells, endothelial cells, smooth muscle cells,
cardiac myocytes, etc. (Raizada et al., 2007). Activated NF-kB
upregulates endothelin production and genes encoding proteins
involved in apoptosis, cell growth (e.g., fibroblast growth factors
[FGFs], transforming growth factor-beta [TGF-β], platelet-
derived growth factors [PDGF], vascular endothelial growth
factor [VEGF], etc.), inflammation (e.g., vascular cell adhesion
protein 1 [VCAM1], intercellular adhesion molecule 1 [ICAM1],
monocyte chemoattractant protein 1 [MCP1], etc.), coagulation
(e.g., plasminogen activator 1, tissue factor, etc.,) and extracellular
matrix deposition (e.g., collagen-1, fibronectin, etc.) leading to
fibrosis and end-organ damage in the kidney, heart, vasculature,
etc. (Raizada et al., 2007). Moreover, NF-kB could upregulate the
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iNOS gene resulting in excessive NO production which easily
forms ONOO− reacting with O2·− (Raizada et al., 2007).
Systemic Oxidative/Nitrative Stress and
Atherosclerosis in CKD
As the renal function progressively declines, the level of the
anti-atherogenic high-density lipoprotein (HDL) also declines
and the produced form is dysfunctional due to the reduced
synthesis of its component apolipoprotein-A1 (apo-A1) in
the liver (Schiffrin et al., 2007). Moreover, higher levels of
the atherogenic low-density lipoprotein (LDL) cholesterol and
lipoprotein(a) [Lp(a)] is found with declining of the kidney
function (Baigent et al., 2000; Kumar et al., 2014). Accumulation
of LDL cholesterol activates the RAAS and also induces the
overexpression of the angiotensin type 1 receptor (AT1) further
aggravating oxidative/nitrative stress and inflammation resulting
in endothelial dysfunction and accelerated atherosclerosis
(Kaysen and Eiserich, 2004;Methe andWeis, 2007; Schiffrin et al.,
2007; Kumar et al., 2014). Angiotensin II causes hypertension not
only via vasoconstriction and atherosclerosis but also activates
vascular NADPH oxidase which produces O2·− (Methe and
Weis, 2007; Kumar et al., 2014). It inactivates NO via the
formation of ONOO− leading to smooth muscle hypertrophy
and proliferation, hypertension, atherosclerosis and heart failure
(Methe and Weis, 2007; Kumar et al., 2014). Another major
player in the acceleration of vascular injury and atherosclerosis
is the elevated level of myeloperoxidase (MPO) which is present
in leukocytes, monocytes and tissue macrophages, and promotes
the peroxidation of LDL cholesterol (Schiffrin et al., 2007;
Kumar et al., 2014). The chronic inflammatory state also triggers
vascular injury and premature atherosclerosis which is more
characteristic in younger CKD patients (Kumar et al., 2014). In
turn, dyslipidemia is also an important factor in the development
of the chronic inflammatory state and atherosclerosis (Kaysen
and Eiserich, 2004).
PATHWAYS OF CARDIAC
OXIDATIVE/NITRATIVE STRESS IN T4CRS
Abundant data have linked the cardiac overproduction of
ROS/RNS to the development of LVH and heart failure in
preclinical and clinical studies (see for reviews: Ungvári et al.,
2005; Maack and Böhm, 2011; Osterholt et al., 2013; Varga et al.,
2015). However, most of the experimental studies regarding
the role of cardiac ROS/RNS in the development of LVH and
heart failure used hypertension-induced or diabetic models.
In T4CRS, CKD-specific factors and mechanisms might also
contribute to the development of LVH and heart failure. There
are only a limited number of studies available in the literature
which investigates the role of oxidative/nitrative stress in the
development of LVH and heart failure in CKD. Therefore, in
this section, we collected studies which describe both renal and
cardiac function and/or morphology and investigate the role of
ROS/RNS in the development of uremic cardiomyopathy.
Cardiac Oxidative/Nitrative Stress in
T4CRS in Preclinical Studies
Based on experimental studies investigating the role of CKD-
induced cardiac oxidative/nitrative stress, the over-activation
of NADPH-oxidase (Goux et al., 2011; Suematsu et al., 2018),
especially its NOX4 (Bai et al., 2009; Fukunaga et al., 2012;
Kuczmarski et al., 2014; Han et al., 2015; Liu et al., 2015)
and NOX2 isoforms (Yin et al., 2016), uncoupled eNOS and
iNOS (Chang et al., 2015; Oosterhuis et al., 2017) are the main
sources of increased cardiac ROS/RNS production in T4CRS.
Mitochondrial dysfunction is also supposed to play a major role
in the development of heart failure in T4CRS (Correa et al.,
2013; Hernandez-Resendiz et al., 2015; Taylor et al., 2015). Chang
et al. found that mild CKD induced by unilateral nephrectomy
impaired cardiac relaxation in Sprague-Dawley rats (Chang
et al., 2015). They also showed that impaired cardiac relaxation
was associated with increased NO-dependent nitrosylation of
sarcoendoplasmic reticulum calcium ATPase 2a (SERCA2a) due
to increased iNOS expression and uncoupled eNOS (Chang
et al., 2015). The reduced cardiac bioavailability of NO is also
described in T4CRS (Chen et al., 2014). Some studies reported
impaired antioxidant defense mechanisms in the heart in T4CRS.
According to these studies, reduced SOD (Sener et al., 2004a,b;
Chen et al., 2014; Kuczmarski et al., 2014; Suematsu et al., 2018),
and CAT (Sener et al., 2004a; Bock and Gottlieb, 2010) activities;
(García-Trejo et al., 2016) and reduced cellular GSH (Sener et al.,
2004b, 2007) and GST (Correa et al., 2013) levels seems to be
characteristic features of uremic cardiomyopathy.
Oxidative/Nitrative Stress in T4CRS in
Clinical Studies
There are only a limited number of clinical studies investigating
the direct link between oxidative/nitrative stress and the
development of LVH and heart failure in T4CRS. In a
clinical cohort study, plasma GSH levels correlated with the
degree of cardiac dysfunction checked by speckle tracking
echocardiography in children with ESRD (Al-Biltagi et al., 2016).
In another study, a cross-sectional analysis recruiting 78 adults
with stage 3-4 CKD (eGFR: 25–60mL/min) revealed that elevated
plasma F2-isoprostane level as a marker of oxidative stress was
associated with reduced heart rate variability (Fadaee et al.,
2017). Reduced heart rate variability is a marker of cardiac
autonomic dysfunction and a risk factor for fatal arrhythmias
and sudden cardiac death (Fadaee et al., 2017). CKD patients
often have lipoprotein abnormalities including, e.g., increased
remnant particles, triglycerides, and oxidized LDL as a byproduct
of oxidative stress, and both deficiency and dysfunction of HDL
which are well-known cardiovascular risk factors (Kennedy et al.,
2013). Paraoxonase (PON-1) is an HDL-associated glycoprotein
and is believed to be responsible for several systemic antioxidant
activities of HDL, including, e.g., protective effects against
oxidation of lipoproteins and phospholipids (Kennedy et al.,
2013). Serum PON-1 function is characterized by its arylesterase
activity. In a prospective cohort study recruiting 630 CKD
patients has been shown that decreased serum arylesterase
Frontiers in Physiology | www.frontiersin.org 7 November 2018 | Volume 9 | Article 1648
Sárközy et al. Oxidative Stress in Cardio-Renal Syndrome and Sarcopenia
activity predicted higher risk for long-term cardiovascular events
(e.g., heart attack, stroke, or death) (Kennedy et al., 2013).
MODULATION OF OXIDATIVE/NITRATIVE
STRESS IN T4CRS
Modulation of oxidative/nitrative stress in T4CRS can be
achieved by different approaches. Theoretically, the prevention
or treatment of CKD could be the most effective way to
eliminate its oxidative/nitrative stress triggering effect and
cardiovascular complications. However, CKD is a chronic,
progressive disease and the maintenance or prevention of its
progression is a major clinical challenge. To the best of our
knowledge, there are no pharmaceutical approaches in the
clinical practice to specifically target cardiac oxidative/nitrative
stress in T4CRS. A therapeutic option is that several well-known
pharmaceuticals used for the treatment of the cardiovascular
complications of CKD have a complex mechanism of action
which might include antioxidant properties. Another therapeutic
option could be the administration of antioxidant molecules
and natural products to decrease cardiac oxidative/nitrative
stress. There is a growing interest in nutraceuticals instead of
chemically synthesized compounds to treat or prevent certain
diseases by modulating oxidative/nitrative stress. Nutraceuticals
include a wide range of products including, e.g., dietary
supplements, natural herbal products, isolated nutrients, etc.
(Csonka et al., 2016). Nutraceuticals could have anti-oxidant
properties due to their unique composition of different
antioxidant compounds (Csonka et al., 2016). The third
therapeutic option is the induction of endogenous enzymatic
antioxidant mechanisms or blockage of the pro-oxidant enzymes,
which might be appropriate ways to decrease the systemic and
cardiac oxidative/nitrative stress in T4CRS. These therapeutic
options could also be combined. In this section, we focus on
various pharmaceuticals, nutraceuticals, some novel therapeutic
modalities, and even physical exercise as possible modulators of
CKD-induced oxidative/nitrative stress in T4CRS.
Pharmaceuticals Modulating
Oxidative/Nitrative Stress in T4CRS in
Preclinical Studies
Angiotensin II Type 1A Receptor Blockers in Single or
Combination Therapy
It has been shown that 12-week treatment with the AT1
receptor blocker valsartan (sc. 1 mg/kg/day administered by
osmotic minipumps) or AT1 KO genotype could improve
cardiac remodeling, both systolic and diastolic dysfunction and
oxidative DNA damage in partially nephrectomized mice (Li
et al., 2007) (Table 1). A novel therapeutic approach in the
therapy of chronic heart failure is the increase of the levels
of vasoactive peptides including natriuretic peptides (A-type,
B-type and C-type natriuretic peptides) which can ameliorate
cardiac hypertrophy and remodeling (Li et al., 2007; Suematsu
et al., 2018). The expression of these vasoactive peptides
can be increased via the blockage of neprilysin which is a
key enzyme in the breakdown of these peptides (Suematsu
et al., 2018). Combined therapy with the neprilysin inhibitor
prodrug sacubitril and AT1 blocker valsartan (60 mg/kg) for
8 weeks could attenuate cardiac hypertrophy and fibrosis in
rats with 5/6 nephrectomy (Suematsu et al., 2018) (Table 1).
In this study, the combination therapy could decrease the
left ventricular levels of NOX4, MPO, and the NADPH-
oxidase subunit gp91phox in the partially nephrectomized rats
(Suematsu et al., 2018) (Table 1). Moreover, it could increase
the levels of eNOS, Nrf2, Cu-SOD, Zn-SOD, HO-1, CAT,
GSH-Px, and ATP-synthase in rats with CKD (Suematsu
et al., 2018) (Table 1). It has been reported that cardiac
function and fibrosis could be improved by the AT1 blocker
losartan or combination treatment (NF-inhibitor PDTC +
NO-donor molsidomine + SOD mimetic tempol) or losartan
+ combination treatment + metoprolol (Table 1). However,
renal fibrosis was most effectively decreased by the losartan +
combination treatment + metoprolol in this study (Oosterhuis
et al., 2017).
Renalase
Circulating catecholamines could be degraded by renalase
which is a soluble mono-amino oxidase secreted by the kidneys
(Yin et al., 2016). It has been demonstrated that renalase
supplementation by adenoviral transduction attenuated
hypertension, LVH, fibrosis and the cardiac expression
of NADPH-oxidase components gp91phox, p47phox, and
p67phox in partially nephrectomized rats (Yin et al., 2016)
(Table 1).
NO Donor Molsidomine
Bongartz et al. found that 5/6 nephrectomy impaired left
ventricular systolic function in male inbred Lewis rats fed
with NaCl enriched chow; however, molsidomine (NO
donor) treatment for 5 weeks improved heart function and
creatinine clearance (Bongartz et al., 2010). Molsidomine
increased NO metabolite excretion but did not increase
3-nitrotyrosine content in the heart, liver or kidney
tissues (Bongartz et al., 2010) (Table 1). In this study,
the cardiac expression of constitutive isoforms of NOS
(nNOS, eNOS) was not changed; however, iNOS expression
was decreased by molsidomine (Bongartz et al., 2010)
(Table 1).
CysLT1 Receptor Antagonist Montelukast
Four-week treatment with the selective CysLT1 receptor
antagonist anti-inflammatory drug montelukast (10 mg/kg
i.p.) could reduce cardiac fibrosis, inflammation, MPO and
MDA levels and increase cardiac glutathione levels and total
antioxidant capacity in male 5/6 nephrectomized rats (Sener
et al., 2007) (Table 1).
Oral Charcoal Adsorbent AST-120
Twenty-week treatment with the oral charcoal adsorbent AST-
120 which reduces the levels of circulating uremic toxins (e.g.,
indoxyl sulfate) could improve LVH, fibrosis and systemic
oxidative stress in doxorubicin plus right nephrectomy-induced
CKD in rats (Fujii et al., 2009) (Table 1).
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TABLE 1 | Pharmaceuticals modulating oxidative/nitrative stress in T4CRS in preclinical studies.
Experimental
model
Age/body
weight
FUP
time
Characteristics
of HF
Molecular markers
of HF
Markers of cardiac
oxidative/nitrative stress
Protective
agent
References
1 AT1 KO and WT
mice (C57BL/6
background)
10
weeks
12
weeks
↑ LVSP,
↓ EF and ±dP/dt,
↓ capillary density
myocardial fibrosis
↑ MMP-2 and 9,
↓ TIMP-1,
↑ TGF-β,
↑ PI3K/Akt pathway,
↑ DNA and cell membrane
oxidative damage
AT1 receptor
blockade
(valsartan)
Li et al., 2007
2 5/6 STNX male
Sprague-Dawley
rats
N/A 8 weeks ↑ HW/BW
↑ cross sectional area
of cardiomycytes,
↑ SBP,
cardiac and aortic
fibrosis,
↓ mitochondrial mass,
↓ ATP-synthase
↑ β-MHC, tropomyosin,
↑ collagen, TGFβ,
FGF-23
↑cardiac protein carbonyl
content;
↑ MCP-1, MPO, COX-2,
↑ NOX4, gp91 phox,
↓ Cu/Zn SOD, CAT,
GSH-Px, HO-1, eNOS
LCZ696
(Sacubitril/
valasrtan)
Suematsu et al.,
2018
3 Male Lewis rats
with chronic
renocardiac
syndrome (5/6
STNX, fed with 6%
NaCl
supplemented
chow, left coronary
ligation)
180-
200 g
16
weeks
↓ EF, ↓ heart rate;
↓ cardiac output;
↓ stroke volume
↑ cardiac BNP mRNA,
↑ cardac fibrosis area
thiobarbituric acid reactive
substances excretion in
urine
losartan;
PDTC +
molsidomine +
tempol;
PDTC +
molsidomine +
tempol +
metoprolol
Oosterhuis et al.,
2017
4 5/6 STNX male
Sprague-Dawley
rats
200–
250 g
6 weeks ↑ HW/BW
↑ SBP
↑ cross sectional area
of cardiomyocytes
interstitial fibrosis and
ECM deposition
↑ mRNA levels of
TGF-β, collagen I and
III, TNF-α, IL-6, MCP-1
↑ phospho-ERK1/2,
p38 MAPK
↑ expressions of gp91phox,
p47phox, p67phox
Renalase Yin et al., 2016
5 5/6 STNX male
Lewis rat fed with
NaCl enriched
chow
180–
200 g
8 weeks ↑ LV mass,
↑ EDV and ESV,
↓ EF and cardiac
output,
↑ SBP, DBP,
N/A ↑ nNOS Molsidomine Bongartz et al.,
2010
6 5/6 STNX male
Wistar rats
200–
250 g
4 weeks fibrosis; degenerated
cardiac muscle with
vascular congestion
↑ collagen content ↓ plasma antioxidant
capacity,
↓ cellular GSH level,
↑ increased lipid
peroxidation,
Montelukast Sener et al., 2007
7 Doxorubicin+right
NTX male Lewis
rat
8-week-
old
20
weeks
LVH, myocardial and
perivascular fibrosis
↑ collagen content ↑ number of 8-OHdG- and
acrolein-posive cells
AST-120 Fujii et al., 2009
8 5/6 STNX male
Wistar rats
200–
250 g
4 weeks N/A N/A ↑ lipid peroxidation and
carbonyl concentration
(aorta, heart, plasma)
↓ GSH (aorta, heart,
plasma),
↓ plasma SOD, GSH-Px
and CAT activity
Melatonin Sener et al., 2004a
5/6 STNX, 5/6 subtotal nephrectomy; 8-oxodG, 8-oxo-7,8-dihydro-2’-deoxyguanosine; AT1 KO, angiotensin II receptor type 1 knock out; ATP, adenosine triphosphate; BNP, B-type
natriuretic peptide; β-MHC, beta myosin heavy chain; BW, body weight; CAT, catalase; COX-2, cyclooxygenase-2; Cu, copper; DBP, diastolic blood pressure; DNA, deoxyribonucleic
acid; ECM, extracellular matrix; EDV, end diastolic volume; EF, ejection fraction; eNOS, endothelial nitric oxide synthase; ERK-1/2, extracellular signal-regulated protein kinases 1 and 2;
ESV, end systolic volume; FGF-23, fibroblast growth factor-23; FUP, follow-up; gp91, NOX subunit; GSH, glutathione; GSH-Px, glutathione peroxidase; GST, glutathione S-transferase;
IVS, interventricular septum; H2O2, hydrogen peroxide; HO-1, heme oxygenase-1; HW, heart weight; IL-6, interleukin-6; LV, left ventricular; LVDP, left ventricular diastolic pressure; LVESD,
left ventricular end-systolic diameter; LVSP, left ventricular systolic pressure; MCP-1, monocyte chemoattractant protein-1; MMP, matrix metalloprotease; MPO, myeloperoxidase; NaCl,
Natrium chloride; NOX4, NADPH oxidase 4; p38 MAPK, p38 mitogen-activated protein kinase; PI3K/Akt, phosphoinositide 3-kinase/Akt pathway; SBP, systolic blood pressure; SOD,
superoxide dismutase; TGF-β:transforming growth factor-beta; TIMP, tissue inhibitor of matrix metalloprotease; Zn, zinc.
Melatonin
Treatment with the pineal gland hormone melatonin (10 mg/kg
i.p.) for 4 weeks was also reported to reduce cardiac MDA level
and protein carbonylation and increase cardiac GSH levels in
male 5/6 nephrectomized rats due to its antioxidant and free
radical scavenging features (Sener et al., 2004a) (Table 1).
Pharmaceuticals Modulating
Oxidative/Nitrative Stress in T4CRS in
Clinical Studies
Statins
The cholesterol-lowering drugs statins could markedly reduce
the risk of cardiovascular mortality in the general population. In
Frontiers in Physiology | www.frontiersin.org 9 November 2018 | Volume 9 | Article 1648
Sárközy et al. Oxidative Stress in Cardio-Renal Syndrome and Sarcopenia
contrast, statins had less, or no benefit on CVD in hemodialysis
patients in large clinical trials (4D with 1255 dialyzed T2DM
patients, AURORA with 2766 ESRD patients, and SHARP with
3023 dialyzed and 6247 non-dialyzed CKD patients) (Wanner
et al., 2005; Fellström et al., 2009; Baigent et al., 2011). Moreover,
Wagner et al. found no correlation between serum oxidized LDL
level and major cardiac events in both dialyzed and non-dialyzed
CKD patients using the data of the AURORA and LURIC studies
(Wagner et al., 2017). These results suggest that the development
of cardiovascular disease is atypical and complex in CKD.
Nutraceuticals Modulating Oxidative
Stress in T4CRS in Preclinical Studies
Curcumin
Curcumin is a yellow pigment with polyphenol structure in curry
spice, turmeric, and to lesser extent ginger (Correa et al., 2013).
In partially nephrectomized rats, curcumin used for 7 days as a
pretreatment before operations and treatment for 60 days could
preserve ejection fraction, reduce cardiac lipid peroxidation and
increase CAT and glutathione-S-transferase (GST) levels (Correa
et al., 2013) (Table 2).
Allicin
Treatment with the garlic extract component allicin (40
mg/kg/day p. os) for 6 weeks attenuated hypertension, LVH,
cardiac lipid and protein oxidation and elevated the levels of
antioxidant enzymes including SOD, CAT, and GSH-Px in male
5/6 nephrectomized rats (García-Trejo et al., 2016) (Table 2).
L-carnitine
L-carnitine is a cofactor playing a role in the transport of long-
chain fatty acids into the mitochondria, where they fuel the beta-
oxidation to produce energy for the cell (Hurot et al., 2002).
L-carnitine deficiency is uncommon in the healthy population
consuming enough protein. In contrast, hemodialysis patients
might develop carnitine deficiency due to the elimination of
carnitine during dialysis, gastrointestinal malabsorption, altered
transport mechanisms through membranes, decreased renal
synthesis, or increased carnitine requirements (Hurot et al.,
2002). It has been showed that L-carnitine (500 mg/kg i.p.)
administration for 4 weeks could reduce the lipid peroxidation
marker MDA and increase the antioxidant glutathione level both
in the plasma and heart in partially nephrectomized rats (Sener
et al., 2004b) (Table 2).
Nutraceuticals Modulating
Oxidative/Nitrative Stress in T4CRS in
Clinical Studies
L-carnitine
A clinical pilot study enrolling 12 ESRD patients showed that L-
carnitine (20 mg/kg i.v.) supplementation for 8 weeks increased
the time to fatigue, plasma GSH level, and GSH-Px activity
and decreased submaximal heart rate, respiratory quotient, and
plasma lactate, MDA and protein carbonyl levels after cycling
exercise (Fatouros et al., 2010).
Vitamin E
The SPACE study enrolling 196 ESRD patients found that 800
IU/day vitamin E as antioxidant supplementation could reduce
the CVD endpoints and myocardial infarction in hemodialysis
patients with pre-existing cardiovascular disease (Boaz et al.,
2000).
Coenzyme Q10 (CoQ10)
CoQ10 moves electrons from complexes 1 and 2 to complex 3
in the mitochondria (Small et al., 2012). CoQ10 depletion might
result in disturbances in the mitochondrial electron transport
leading to elevated ROS/RNS production and decreased ATP
generation (Small et al., 2012). Plasma CoQ10 concentration has
been shown to be decreased in hemodialysis patients (Rivara
et al., 2017). It has been demonstrated in a dose-escalation
study recruiting 20 hemodialysis patients that oral CoQ10
supplementation for 8 weeks is also safe and well-tolerable
in a dose of 1,800 mg/day and could reduce plasma isofuran
concentration which is a marker of systemic oxidative stress
(Yeung et al., 2015). Another clinical pilot study enrolling 65
hemodialysis patients showed that CoQ10 administration for 4
months at a dose of 1,200 mg/day could reduce the plasma levels
of F2-isoprostanes which are systemic oxidative stress markers,
however, it has no significant effect on the cardiac biomarkers
cTnT and NT-pro-BNP (Rivara et al., 2017).
Novel Pharmacological Approaches
Modulating Oxidative/Nitrative Stress in
T4CRS in Preclinical Studies
Apocynin
Apocynin is an assembly inhibitor of NOX possibly via the
inhibition of the expressions of NOX subunits and translocation
from the cytoplasm to the membrane (Liu et al., 2015). The
cardioprotective effects of apocynin are related to the decrease of
NOX-dependent oxidative stress, but the potential downstream
mechanisms are not clear yet (Liu et al., 2015). Liu et al.
reported that apocynin treatment (dosed in drinking water, 1.5
mmol/L, for 8 weeks) attenuated the oxidative stress-induced
ERK1/2 phosphorylation and cardiac fibrosis and HFrEF in 5/6
nephrectomized rats via inhibiting NADPH oxidase (Liu et al.,
2015) (Table 3). Apocynin also inhibited the upregulation of
the important profibrotic factor FGF-2 (Liu et al., 2015). Zhang
et al. also found that apocynin improved cardiac hypertrophy
and fibrosis in CKD rats 8 weeks after 5/6 nephrectomy (Zhang
et al., 2015). Han et al. showed that treatment with the protein-
bound uremic toxin P-cresyl sulfate (PCS) upregulated the
protein expression levels of the NADPH oxidase subunits p22phox
and p47phox in H9c2 cardiac myoblasts (Han et al., 2015).
Moreover, PCS treatment for 8 weeks (100 mg/kg/day p.os)
further augmented cardiac fibrosis and diastolic dysfunction
in 5/6 nephrectomized mice (Han et al., 2015). The diastolic
dysfunction could be partially restored by apocynin in the PCS-
treated CKD mice (Han et al., 2015) (Table 3).
Sodium Zinc Dihydrolipoylhistidinate
Sodium zinc dihydrolipoylhistidinate (DHLHZn) is a novel
Zn2+/dihydrolipoic acid derivate antioxidant drug. Left atrium
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TABLE 2 | Nutraceuticals modulating oxidative/nitrative stress in T4CRS in preclinical studies.
Experimental
model
Age/body
weight
FUP
time
Characteristics
of HF
Molecular
markers of HF
Markers of cardiac
oxidative/nitrative stress
Protective
agent
References
1 5/6 STNX male
Wistar rats
280–300 g 60 days ↑ HW/BW,
↑ IVS,
↓ LVDd and LVSd,
↓ EF,
↑ SBP,
↓ LVDP,
hypertrophic
remodelling
mitochondrial
disintegrity,
mitochondrial
dysfunction
↑ ROS generation,
↑ lipidperoxidation,
↑ protein oxidation,
↓ CAT activity and GST level
Curcumin Correa et al.,
2013
2 5/6 STNX male
Wistar rats
280–300 g 6 weeks ↑ LV/BW,
↑ SBP,
↓ coronary
perfusion,
pressure,
↓ LV performance
N/A ↑ lipid and protein oxidation,
↓ Nrf2, CAT, SOD, GSH-Px
Allicin García-Trejo
et al., 2016
3 5/6 STNX male
Wistar rats
200–250 g 4 weeks - - ↑ lipid peoroxidation (heart,
aorta and plasma),
↓ GSH level, (heart, plasma)
↓ plasma SOD and GSH-Px
activities
L-Carnitine Sener et al.,
2004b
5/6 STNX, 5/6 subtotal nephrectomy; BW, body weight; CAT, catalase; DNA, deoxyribonucleic acid; EF, ejection fraction; eNOS, endothelial nitric oxide synthase; FUP, follow-up; GSH,
glutathione; GSH-Px, glutathione peroxidase; GST, glutathione S-transferase; IVS, interventricular septum; HO-1, heme oxygenase-1; HW, heart weight. LV, left ventricular; LVDd, left
ventricular end-diastolic diameter; LVDP, left ventricular diastolic pressure; LVSd, left ventricular end-systolic diameter; LVSP, left ventricular systolic pressure; ROS, reactive oxygen
species; SBP, systolic blood pressure; SOD, superoxide dismutase.
isolated from 5/6 nephrectomized rats showed greater left atrial
diameters and fibrosis, increased left atrial protein expression of
NOX4 and subunits gp91phox and p47phox. DHLHZn treatment
(5 mg/kg/day s.c. by osmotic minipump) successfully attenuated
the atrial fibrosis and the overexpression of NOX4, gp91phox,
p47phox in the left atrium (Fukunaga et al., 2012) (Table 3).
microRNAs (miRs)
It has been recently recognized that small non-coding RNAs
including miRs (approximately 18–25 nucleotides in length)
play a myriad of roles in physiological and pathophysiological
mechanisms by repression of the translation or destabilization
of the mRNA of various target genes (Djebali et al., 2012).
Therefore, they might act as fine tuners or on/off switches of the
gene expression (Djebali et al., 2012). Certain miRs (e.g., miR-1;
miR-25, miR-21, miR-210, the miR-200 family, miR-212, miR-
181a, etc.) have been implicated in cellular oxidative/nitrative
stress response in CVD in experimental studies (Magenta et al.,
2013; Varga et al., 2013; Yildirim et al., 2013; Azzouzi et al.,
2015; Csonka et al., 2016; Sárközy et al., 2018). In contrast,
experimental data are very limited to the connection between
miRs and CKD-induced oxidative/nitrative stress in cardiac
pathologies. Down-regulation of the anti-fibrotic miR-29 (Panizo
et al., 2017; Drummond et al., 2018) and miR-30c (Panizo
et al., 2017), as well as the up-regulation of the pro-fibrotic
miR-21 (Chuppa et al., 2018), was observed in the heart
of rats suffering from CKD. However, none of these studies
investigated the link between the expressional change of miRs
and cardiac oxidative/nitrative stress in CKD. In the future,
miR-modulators might become new therapeutic approaches in
T4CRS. Nevertheless, caution is needed with miR-modulators.
Potentially harmful effects of miR-modulators could happen in
non-targeted tissues (on-target side effects) or targeted tissues
(off-target side effects including, e.g., chemical toxicity or
unwanted gene expression changes). Therefore, the development
of tissue-specific delivery techniques of miR-modulators is
needed.
Physical Exercise and Oxidative/Nitrative
Stress in T4CRS in Preclinical Studies
Bai et al. demonstrated that voluntary running exercise for 4
weeks resulted in the development of LVHwhich was a functional
adaptation in rats with CKD (Bai et al., 2009) (Table 4). In this
study, exercise could ameliorate the upregulation of NOX-4 and
NADPH oxidase subunits in the CKD rats (Bai et al., 2009)
(Table 4). Another study showed that 4 weeks long voluntary
wheel running preserved cardiac function, cardiac eNOS protein
level, and NO bioavailability and decreased cardiac iNOS
protein level in Sprague-Dawley rats underwent 5/6 nephrectomy
(Kuczmarski et al., 2014) (Table 4). Chen et al. found that
running or swimming reduced cardiac fibrosis in doxorubicin-
induced CKD model. Both exercise regimes could increase the
bioavailability of NO and the SOD level and decrease MDA level
(Chen et al., 2014) (Table 4).
Physical Exercise and Oxidative/Nitrative
Stress in T4CRS in Clinical Studies
In CKD patients, muscle catabolism and wasting are markedly
common, and these result in decreased muscle strength, declines
in physical function and activity (Wilund et al., 2010). Physical
inactivity aggravates these functional changes and also triggers
CVD (Wilund et al., 2010). Therefore, disability significantly
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TABLE 3 | Novel pharmacological approaches modulating oxidative/nitrative stress in T4CRS in preclinical studies.
Experimental
model
Age/body
weight
FUP
time
Characteristics
of HF
Molecular
markers of HF
Markers of cardiac
oxidative/nitrative stress
Protective
agent
References
1 5/6 STNX male
Sprague-Dawley rats,
1–3-day-old neonatal
Sprague-Dawley rats
(cell culture)
160 ± 20g 8 weeks ↑ LVPWd, LVESD,
↓ left ventricular
fractional shortening
and EF
↑ interstitial fibrosis,
FGF-2
MDA, superoxide anion,
mitochondrial ROS
production, NOX activity
Apocynin Liu et al.,
2015
2 5/6 STNX male
Sprague-Dawley rats,
H9c2 rat cell line
160-180 g 8 weeks ↑ LVPWd,
↓ EF
↑ interstitial fibrosis,
ANP, β-MHC, cardiac
fibrosis index, cardiac
collagen volume
fractions
sEH (soluble epoxide
hydrolase), EET
(epoxyeicosatrienoic acids)
Apocynin Zhang et al.,
2015
3 5/6 STNX male
C57BL/6J mice
5 weeks 8 weeks ↓ FS, EF, E/A ratio,
↑ interstitial and
perivascular collagen
↑ collagen, caspase-3
activity (apoptosis)
↑ p22phox and p47phox
expressions, ↑ intracellular
ROS production
Apocynin Han et al.,
2015
4 5/6 STNX male
Sprague-Dawley rats
8 weeks 4 weeks ↑ HW/BW,
↑ SBP,
↑ LA cardiomyocyte
diameter, ↑ interatrial
conduction time and
P-wave duration
↑ collagen I and III,
α-SMA
↑ protein expression of
NOX4, gp91phox, Nox4,
p47phox
Sodium zinc
dihydrolipoylhis
tidinate
(DHLHZn)
Fukunaga
et al., 2012
5/6 STNX, 5/6 subtotal nephrectomy; α-SMA, alpha smooth muscle actin; ANP, A-type natriuretic peptide; β-MHC, beta-myosin heavy chain; BW, body weight; E/A, early wave/atrial
wave (diastolic parameter); EF, ejection fraction; FGF-2, fibroblast growth factor-2; FS, fractional shortening; FUP, follow-up; HW, heart weight; LA, left atrial; LVSED, left ventricular
end-systolic diameter; LVPWd, left ventricular posterior wall thickness in diastole; MDA, malondialdehyde; SBP, systolic blood pressure; p22phox, NOX subunit; p47phox, NOX subunit;
ROS, reactive oxygen species.
TABLE 4 | Physical exercise and oxidative/nitrative stress in T4CRS in preclinical studies.
Experimental
model
Age/body
weight
FUP time Characteristics
of HF
Molecular markers
of HF
Markers of cardiac
oxidative/nitrative stress
Protective
agent
References
1 5/6 STNX female
Sprague-Dawley rats
220–240 g 4 weeks ↑ atrial pressure N/A ↑ NOX4, p22phox,
gp91phox, Cu/Zn SOD, Mn
SOD,
voluntary
running
exercise
Bai et al., 2009
2 5/6 ablation–infarction
male Sprague-Dawley
rats
12 weeks 8 weeks LVH, systolic and diastolic
dysfunction, ↓ cardiac work
and rate pressure,
↓ response to left arterial
filling and aortic pressure
perturbation,
↓ cardiac output,
↓ stroke volume and stroke
work post-ischemia,
N/A ↑ iNOS level,
↓ eNOS level,
↑ H2O2 production,
↓ SOD-1,
↑ GSH-Px1/2, CAT
voluntary
wheel
running
Kuczmarski et al.,
2014
3 Doxorubicin-induced
CKD male
Sprague-Dawley rats
4 weeks 11 weeks ↑ HW/BW,
↓ capillary/fiber ratio,
fibrosis
↑ cardiotrophin-1,
collagen, IL-6;
↑ gp130, LIFR,
p-STAT, p-JAK
↓ NO and SOD levels,
↑ MDA level
Treadmill
running,
swimming
Chen et al., 2014
5/6 STNX, 5/6 subtotal nephrectomy; BW, body weight; CAT, catalase; CKD, chronic kidney disease; eNOS, endothelial nitric oxide synthase; FUP, follow-up; GSH-Px, glutathione
peroxidase; gp130, glycoprotein 130; H2O2, hydrogen peroxide; HF, heart failure; HW, heart weight; IL-6, interleukin-6; iNOS, inducible nitric oxide synthase; LIFR, leukemia inhibitory
factor receptor; LVH, left ventricular hypertrophy; MDA, malondialdehyde; NOX4, NADPH oxidase 4;; p-JAK, phospho-Janus kinase; p-STAT, signal transducer and activator of
transcription; SOD, superoxide dismutase; Zn, zinc.
reduces the quality of life and raises the mortality risk in ESRD
patients. In a clinical pilot study enrolling 17 hemodialysis
patients have been shown that intradialytic cycling exercise
for 4 months increased performance on shuttle walking test
and reduced the serum thiobarbituric acid reactive substances
(TBARS), which is a marker of oxidative stress (Wilund et al.,
2010). Moreover, exercise could reduce the thickness of the
epicardial fat which is taught to be an inflammatory tissue
secreting cytokines (Mazurek et al., 2003). It lies in close
proximity to the adventitia of the coronary arteries and the
myocardium suggesting that it might play a key role in the
development of CVD (Mazurek et al., 2003).
PATHWAYS OF OXIDATIVE/NITRATIVE
STRESS IN RENAL SARCOPENIA
Not only systemic but also tissue oxidative/nitrative stress seems
to be a major factor leading to renal sarcopenia. In contrast, there
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are only a limited number of studies which investigate skeletal
muscle oxidative/nitrative stress and characterize both renal and
skeletal muscle morphology and/or function in CKD. Therefore,
in this section, we collected the studies which described both
renal and muscle function and/or morphology and investigated
the role of oxidative/nitrative stress in the development of renal
sarcopenia.
Skeletal Muscle Oxidative/Nitrative Stress
in Renal Sarcopenia in Preclinical Studies
Experimental evidence showed that mainly the over-activation
of NADPH-oxidase (Nishikawa et al., 2015; Enoki et al., 2016),
especially its NOX4 isoform (Avin et al., 2016), the mitochondria
(Gortan Cappellari et al., 2017), and iNOS (Chang et al., 2015;
Oosterhuis et al., 2017) are the main sources of increased skeletal
muscle ROS/RNS production in renal sarcopenia. Moreover,
reduced bioavailability of NO due to reduced eNOS expression
is also described in renal sarcopenia (Flisinski et al., 2012, 2017).
Skeletal Muscle Oxidative/Nitrative Stress
in Renal Sarcopenia in Clinical Studies
Crowe et al. investigated oxidative stress markers in skeletal
muscle of ten hemodialysed patients and ten control subjects.
Biopsies were taken from quadriceps femoris muscle and were
analyzed for reduced and oxidized glutathione, SOD, catalase,
protein thiols, MDA, and heat shock proteins (HSP27, HSP60,
and HSP70) (Crowe et al., 2007). ESRD patients had muscle
atrophy in both types I and II fibers, and reduced MDA content
and catalase activity (Crowe et al., 2007). In contrast, total
glutathione and heat shock protein levels were elevated, and
other measured parameters were unchanged (Crowe et al., 2007).
According to these findings, there is no clear link between
oxidative stress and muscle fiber atrophy in ESRD; however,
the small sample size is a limiting factor here. Lim et al. tested
the hypothesis that the uremic condition may result in more
damagedmitochondrial DNA (mtDNA) (Lim et al., 2000). In this
study, multiple and diverse mtDNA deletions were found in the
skeletal muscles of 22 ESRD patients (Lim et al., 2000). These
mtDNA deletions were more common in ESRD patients than in
normal populations. High levels of uremic toxins and impaired
antioxidant mechanisms might be responsible for the elevated
oxidative/nitrative stress in dialysis patients (Lim et al., 2000).
MODULATION OF OXIDATIVE/NITRATIVE
STRESS IN RENAL SARCOPENIA
To the best of our knowledge, there are no pharmaceutical or
other approaches in the clinical practice to specifically target
skeletal muscle oxidative/nitrative stress in renal sarcopenia.
The most effective way for modulation of oxidative/nitrative
stress in renal sarcopenia could be the prevention or treatment
of CKD and its cardiovascular complications because T4CRS
and renal sarcopenia could worsen each other. Well-known
and clinically used drugs for the therapy of the cardiovascular
complications of CKD might have antioxidant properties or
reduce the cardiovascular risk in CKD (e.g., RAAS inhibitors)
(see section Modulation of Oxidative/Nitrative Stress in T4CRS)
which might be a therapeutic option. However, the number of
studies is very limited on drugs which directly or indirectly target
skeletal muscle oxidative/nitrative stress in renal sarcopenia. In
this section, we collected both experimental and clinical studies
which examined the effects of various pharmaceuticals on CKD-
induced oxidative/nitrative stress in renal sarcopenia.
Pharmaceuticals Modulating Skeletal
Muscle Oxidative/Nitrative Stress in Renal
Sarcopenia in Preclinical Studies
Unacylated Ghrelin
Ghrelin is a hormone produced by the gastrointestinal tract
and regulates food intake and energy homeostasis (Yanagi et al.,
2018). Acylated ghrelin induces hyperglycemia and reduces the
insulin secretion, and insulin sensitivity (Yanagi et al., 2018).
In contrast, unacylated ghrelin antagonizes these effects (Yanagi
et al., 2018). Incubation of C2C12 myotubes with human uremic
serum resulted in higher mitochondrial ROS generation which
could be ameliorated by unacylated ghrelin (Gortan Cappellari
et al., 2017) (Table 5). In this study, 4-days treatment with
unacylated ghrelin (200mg, s.c. ghrelin injection twice a day)
enhanced mitophagy, normalized oxidative stress, inflammation,
and impaired insulin signaling as well as muscle loss in the
gastrocnemius muscle in 5/6 nephrectomized rats (Gortan
Cappellari et al., 2017) (Table 5).
Oral Charcoal Adsorbent AST-120
The oral adsorbent AST-120 is thought to be able to decrease
the levels of IS (Nishikawa et al., 2015) (Tables 4, 5). Nishikawa
et al. found that AST-120-enriched diet for 8 weeks could reduce
plasma IS levels and superoxide production in the skeletal muscle
in 5/6 nephrectomized mice (Nishikawa et al., 2015) (Tables 4,
5). In this model of CKD, the AST-120 treatment resulted in
better running distances to exhaustion, which was determined by
treadmill tests (Nishikawa et al., 2015) (Table 5).
Pharmaceuticals Modulating Skletal
Muscle Oxidative/Nitrative Stress in Renal
Sarcopenia in Clinical Studies
Creatine Supplementation
ESRD patients undergoing chronic dialysis have severe energy
depletion caused by the decreased phosphoryl-creatine/ATP
ratio in skeletal muscle (Wallimann et al., 2017). Wallimann
et al. summarized in a review that intradialytic creatine
supplementation could prevent mitochondria from oxidative
stress by reducing the production of ROS (Wallimann et al.,
2017).
Novel Approaches Modulating Skeletal
Muscle Oxidative/Nitrative Stress in Renal
Sarcopenia in Preclinical Studies
microRNAs (miRs)
Multiple miRs (e.g., miR-133, miR-23, miR-26, miR-27, miR-
214, miR-182, miR-221/222, miR-486, etc.) are implicated in
muscle cell differentiation and muscle mass regulation in renal
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TABLE 5 | Pharmaceuticals modulating skeletal muscle oxidative/nitrative stress in renal sarcopenia in preclinical studies.
Experimental
model
Age/body
weight
FUP time Characteristics
of HF
Molecular
markers of HF
Markers of skeletal
muscle
oxidative/nitrative stress
Protective
agent
References
Uremic or control
human serum treated
C2C12 myoblasts
N/A 4–7 days N/A N/A High mitochondrial
superoxide production
Unacetylated
ghrelin (UnaG)
Gortan
Cappellari
et al., 2017
1 5/6 STNX male Wistar
rats (M. gastrocnemius)
12 weeks 40 days ↓ body weight
gaining,
↓ muscle mass
↑ muscle
proteolysis and
↑ actin
fragmentation
↑ mitochondrial superoxide
and H2O2 production,
↑ oxidized/total GSH ratio,
↑ ROS production
Unacetylated
ghrelin
C2C12 myoblast N/A 1 day N/A N/A ↑ NADPH oxidase activity - Nishikawa
et al., 2015
2 5/6 STNX male
C57BL/6J mice (M.
Gastrocnemius, M.
Quadriceps, M. Soleus)
6–7 week-old 21 weeks ↓ cell
cross-sectional
area,
↓ mitochondrial
biogenesis and
density,
↓ running distance
and run time to
exhaustion
CD31 staining for
angiogenesis
↑ superoxide production,
↑ NADPH oxidase subunits
expression and activity
AST-120 -oral
absorbent
5/6 STNX, 5/6 subtotal nephrectomy; FUP, follow-up; GSH, glutathione; H2O2, hydrogen peroxide.
FIGURE 4 | Interrelationship between T4CRS and sarcopenia. CKD, chronic kidney disease; CRS, cardio-renal syndrome; HF, heart failure; miR, microRNA; RNS,
reactive nitrogen species; RAAS, renin–angiotensin–aldosterone system; ROS, reactive oxygen species; SNS, sympathetic nervous system.
sarcopenia targeting the elements of the IGF1, myostatin and
GH-mediated pathways (Mak and Cheung, 2012; Hudson et al.,
2014; Wang et al., 2017). However, it is unclear whether these
or other miRs are regulated by oxidative/nitrative stress in renal
sarcopenia. Further studies are needed for the investigation
of the direct link between skeletal muscle oxidative/nitrative
stress and expression changes of miRs in renal sarcopenia. In
the future, miR modulators might represent new therapeutic
approaches for muscle wasting also in renal sarcopenia.
Nevertheless, miR targets need to be specific to skeletal
muscle, since undesirable side effects may develop in other
organs.
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CONCLUSIONS AND PERSPECTIVES
In CKD, cardiac and skeletal muscle injury develops as
a consequence of a myriad of maladaptive mechanisms
including systemic inflammation and neurohormonal
activation which could be over-activated and perpetuated by
the increased oxidative/nitrative stress. These mechanisms
could participate in the complex interorgan crosstalk
between the kidneys, heart and skeletal muscle. Moreover,
pathological states of one or more of the aforementioned
organs can lead to morphological and functional changes
in other organs. Despite the accumulating evidence based
mainly on preclinical studies, there is no breakthrough
in the treatment of uremic cardiomyopathy. Its treatment
remains largely symptomatic by well-known pharmaceuticals
used for the treatment in other forms of heart failure
(e.g., RAAS inhibitors). Elevated oxidative/nitrative stress
and inflammation are key elements in the complex
pathomechanism and interrelationship between T4CRS and
renal sarcopenia.
In contrast, there are only a limited number of clinical
studies which targets indirectly or directly CKD-induced
oxidative/nitrative stress, and their results are largely
disappointing. Therefore, the thorough understanding of the
mechanisms which lead to perturbations in oxidative/nitrative
metabolism and its relationship with pro-inflammatory,
hypertrophic, fibrotic, cell death and other pathways would help
to develop strategies to counteract systemic and tissue-specific
oxidative/nitrative stress to control the progression of CKD
and the end-organ damages in the heart and skeletal muscle
(Figure 4). Moreover, many of the possible modulators of
oxidative/nitrative stress (e.g., antioxidants, nutraceuticals,
exercise, etc.) require further optimization for application in
CKD patients. Novel therapies (e.g., miR modulators, selective
inhibitors, etc.) which target NADPH oxidase, uncoupled eNOS,
iNOS or mitochondrial ROS generation are also needed.
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